

## **REMARKS**

The Examiner has requested restriction of the present invention in accordance with 37 CFR 1.499 to:

Group I, claim(s) 1, 3-5, 7-10 and 14, drawn to a combination comprising: (a) death receptor ligand, and (b) a histone deacetylase inhibitor of Formula (I).

Group II, claim(s) 2, 6 and 11-13, drawn to a method for the prevention or treatment of proliferative diseases, in a mammal, which comprises treating the mammal with pharmaceutically effective amounts of a combination of: (a) death receptor ligand, and (b) a histone deacetylase inhibitor of formula (I).

Without traverse Applicants elect Group II. Claims 1, 3-5, 7-10 and 14 are withdrawn as not being elected material. Applicants reserve their right to file divisional(s) to nonelected claim(s).

The Examiner has requested a species for examination purposes. Applicants elect the histone deacetylase inhibitor, *N*-hydroxy-3-[4-[[[2-(2-methyl-1*H*-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2*E*-2-propenamide and the death receptor ligand, TRAIL/Apo-2L.

Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,

Novartis Pharmaceuticals Corp.  
Patents Pharma  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-2614

  
\_\_\_\_\_  
Gregory C. Houghton  
Attorney for Applicants  
Reg. No. 47,666

Date: July 17, 2008